What is Supernus Pharmaceuticals, Inc.'s (SUPN) StockRank?

MoatMap's StockRank for Supernus Pharmaceuticals, Inc. (SUPN) is 43/100, with a Hold signal. This is a composite score combining Quality (49), Value (35), and Momentum (51) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Supernus Pharmaceuticals, Inc. have an economic moat?

Supernus Pharmaceuticals, Inc. (SUPN) has a Quality factor score of 49/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Supernus Pharmaceuticals, Inc. a buy, hold, or sell?

MoatMap's current signal for Supernus Pharmaceuticals, Inc. (SUPN) is Hold, based on a StockRank of 43/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Supernus Pharmaceuticals, Inc. in?

Supernus Pharmaceuticals, Inc. (SUPN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SUPN

HoldHot Air

Supernus Pharmaceuticals, Inc. · Healthcare · United States · $2.5B · Avg Vol: $36M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-10.5%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for central nervous system (CNS) disorders, including treatments for epilepsy, ADHD, and Parkinson's disease. The company differentiates itself through proprietary drug delivery technologies that enhance therapeutic profiles. It holds a niche position in the complex CNS market, leveraging its specialized development capabilities.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	667.2M	607.5M	661.8M	719.0M	2.5%	830.4M	885.8M	1.4B	38.1%
EPS	1.13	0.02	1.34	-0.68	8.9%	-1.92	—	—	—
Shares	54.3M	54.7M	55.7M	57.5M	+5.9%	58.1M	—	—	—
Debt	444.8M	41.5M	34.3M	41.0M	-54.8%	40.2M	—	—	—
Equity	886.2M	921.5M	1.0B	1.1B	6.2%	—	—	—	—
Op CF	116.8M	111.1M	172.0M	47.3M	-26.0%	19.9M	—	—	—
Inv CF	-216.7M	268.7M	-189.9M	4.1M	—	—	—	—	—
Fin CF	-10.5M	-397.9M	12.2M	9.1M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-9.2%

SMA 50SMA 200

$42.28

RSI (14)

12.3

52W High

$59.68

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-10.8%34.2

ROE

-10.5%34.6

GP/Assets

41.7%79.9

Op. Margin

-2.5%31.3

FCF/Assets

3.2%61.0

Piotroski

431.0

Int. Cover

—N/A

D/E Ratio

0.04x73.5

Current Ratio

2.08x40.4

Value

P/E (TTM)

—N/A

EV/EBITDA

20.1x34.0

P/FCF

55.3x27.1

P/B

2.5x54.3

P/S

3.0x56.1

Div Yield

—N/A

Momentum

52W High %

71%51.7

RS 6M

-35%24.2

SMA 50/200

0.96x45.6

EPS Rev 4W

+2.7%72.0

EPS Rev 12W

+2.7%74.0

EPS Improve

+332%93.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$2.5B

P/E (Forward)

9.8x

Gross Margin

72.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SUPN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SUPN	Supernus Pharmaceuticals, Inc.(you)	$2.5B	43	Hold
CURA.TO	Curaleaf Holdings, Inc.	$2.6B	48	Hold
AMLX	Amylyx Pharmaceuticals, Inc.	$3.9B	30	Sell
HROW	Harrow, Inc.	$1.5B	29	Sell
PBH	Prestige Consumer Healthcare Inc.	$2.5B	67	Buy
XERS	Xeris Biopharma Holdings, Inc.	$1.5B	60	Hold
HIMS	Hims & Hers Health, Inc.	$6.7B	26	Sell
ETON	Eton Pharmaceuticals, Inc.	$1.7B	72	Buy
LQDA	Liquidia Corporation	$6.1B	64	Hold
TKNO	Alpha Teknova, Inc.	$382M	44	Hold

Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%

Supernus Pharmaceuticals, Inc. (SUPN): Stock Score Summary

Supernus Pharmaceuticals, Inc. (SUPN) has a MoatMap StockRank of 43/100 based on Quality (49/100), Value (35/100), and Momentum (51/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$42.28
Market Cap	$2.5B
P/E (Forward)	9.76
Price/Book	2.46
Return on Equity	-10.5%
Return on Invested Capital	-10.8%
Debt/Equity	0.04x
Gross Margin	72.9%
Operating Margin	-2.5%
Revenue Growth	32.4%
Free Cash Flow	$46M

Supernus Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Supernus Pharmaceuticals, Inc.’s (SUPN) StockRank?: MoatMap’s StockRank for Supernus Pharmaceuticals, Inc. (SUPN) is 43/100, with a Hold signal. It is a composite of Quality (49), Value (35), and Momentum (51) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Supernus Pharmaceuticals, Inc. have an economic moat?: Supernus Pharmaceuticals, Inc. (SUPN) has a Quality factor score of 49/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Supernus Pharmaceuticals, Inc. a buy, hold, or sell?: MoatMap’s current signal for Supernus Pharmaceuticals, Inc. (SUPN) is Hold, based on a StockRank of 43/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Supernus Pharmaceuticals, Inc. in?: Supernus Pharmaceuticals, Inc. (SUPN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).